Building Today the Cell Bank for Tomorrow's Therapies
We are focused on the preservation and reprogramming of somatic cells to enable future iPSCs-based therapies and personalized regenerative medicine pathways.
An insurance policy for the therapies of the future
The problem
Advanced therapies, from cell & gene therapy to iPSCs‑based applications, require high-quality raw materials: compatible cells preserved according to stringent regulatory standards. Today, most people do not have a cellular reserve prepared for this scenario.
Our Solution
We have built a ‘personal cell reserve’ platform based on somatic cells from blood, cryopreserved in a certified Swiss biobank, designed to integrate with the emerging pipeline of advanced therapies.
Where We Position Ourselves in the Value Chain
We operate at the intersection of end consumers, clinicians, and advanced therapy development
B2C
MyCells Service for individuals who want to create a personal cell reserve as a biological insurance for their future health
B2B
Services for clinics, specialists, and regenerative/longevity medicine centers seeking to integrate cell preservation into their protocols.
Piattaforma
We are an infrastructure ready to engage with centers developing or applying iPSCs-based therapies and advanced therapy medicinal products (ATMPs).
A Rapidly Growing Market
- The global biobanking market and related services are continuously growing, driven by research, advanced therapies, and personalized medicine.
- The iPSCs-based therapy and cell & gene therapy pipeline is expanding, with a growing number of clinical trials in areas such as neurology, cardiology, metabolism, and oncology.
- Interest is growing among consumers and longevity centers for advanced prevention tools and “biological insurance” based on personal cellular reserves.
Invest in the future
If you wish to explore investment opportunities or strategic partnerships, we are available for targeted meetings to introduce you to our company.